Hydralazine for treatment of severe hypertension in pregnancy: Meta-analysis

British Medical Journal

Volumn 327, Issue 7421, 2003, Pages 955-960

  Magee, Laura A ^a   Cham, Chris ^b   Waterman, Elizabeth J ^b   Ohlsson, Arne ^c   Von Dadelszen, Peter ^a  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDRALAZINE; ISRADIPINE; KETANSERIN; LABETALOL; NIFEDIPINE; PROSTACYCLIN;

ANTIHYPERTENSIVE THERAPY; APGAR SCORE; BRADYCARDIA; BRAIN HEMORRHAGE; BRONCHOSPASM; CESAREAN SECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FATALITY; EPIGASTRIC PAIN; FETUS DISEASE; FLUSHING; HEADACHE; HEART PALPITATION; HEART RATE; HELLP SYNDROME; HUMAN; HYPOGLYCEMIA; HYPOTENSION; HYPOTHERMIA; MATERNAL HYPERTENSION; META ANALYSIS; NECROTIZING ENTEROCOLITIS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN DEATH; NEWBORN DISEASE; OLIGURIA; PERINATAL DEATH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN MANIFESTATION; SOLUTIO PLACENTAE; STILLBIRTH; TACHYCARDIA; TREATMENT OUTCOME; VERTIGO; VISUAL IMPAIRMENT; VOMITING; ARTICLE; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; FETUS HEART RATE; HYPERTENSION; NEWBORN; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRADYCARDIA; FEMALE; HEART RATE, FETAL; HUMANS; HYDRALAZINE; HYPERTENSION; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0142216242     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Rey E, LeLorier J, Burgess E, Lange IR, Leduc L. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ 1997;157:1245-54.
2. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22.
3. Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, et al. The detection, investigation and management of hypertension in pregnancy: executive summary. Aust N Z J Obstet Gynaecol 2000;40:133-8.
4. Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993;100:959-61.
5. Olsen KS, Beier-Holgersen R. Fetal death following labetalol administration in pre-eclampsia. Acta Obstet Gynecol Scand 1992;71:145-7.
6. Vink GJ, Moodley J, Philpott RH. Effect of dihydralazine on the fetus in the treatment of maternal hypertension. Obstet Gynecol 1980;55:519-22.
7. Vink GJ, Moodley J. The effect of low-dose dihydrallazine on the fetus in the emergency treatment of hypertension in pregnancy. S Afr Med J 1982;62:475-7.
8. Waisman GD, Mayorga LM, Camera MI, Vignolo CA, Martinotti A. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol 1988;159:308-9.
9. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ 1999;318:1332-6.
10. Cutler JA. Calcium-channel blockers for hypertension - uncertainty continues. N Engl J Med 1998:338:679-81.
11. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998;16:1823-9.
12. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
13. Ben Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynaecol 1994;101:262-3.
14. Snyder SW, Cardwell MS. Neuromuscular blockade with magnesiumsulfate and nifedipine. Am J Obstet Gynecol 1989;161:35-6.
15. Brown MA, McCowan LM, North RA, Walters BN. Withdrawal of nifedipine capsules: jeopardizing the treatment of acute severe hypertension in pregnancy? Australasian Society for the Study of Hypertension in Pregnancy. Med J Aust 1997;166:640-3.
16. Stevens TP, Guillet R. Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. J Pediatr 1995;127:151-3.
17. Egger M, Smith GD. Principles of and procedures for systematic reviews. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. London: BMJ Books, 2003:23-42.
18. Clarke M, Oxman AD, eds. Cochrane reviewer's handbook 4.2.0. In: Cochrane Library, Issue 2, 2003. www.cochrane.de/cochrane/hbook.htm (accessed 24 Sep 2003).
19. Organization of a systematic review for the Cochrane Neonatal Review Group: guidelines for reviewers and editors. Cochrane Collaboration, 2002. hiru.mcmaster.ca/cochrane/centres/ canadian/neonatal/ checklist.pdf (accessed 16 Sep 2003).
20. Duley L, Farrell B, Spark P, Roberts B, Watkins K, Bricker L et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:1877-90.
21. Duley L, Henderson-Smart DJ. Drugs for rapid treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2002;(4);CD001449.